Metraipolis › archive › dc_e12675f5507f

Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A… — Europe PMC PMID:38976754

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38976754
DOI
10.1371/journal.pmed.1004424
License (as archived)
CC0-1.0
Archived
2026-10-06T17:10:05.408Z
SHA-256 of the archived text
9aa362a6f33aab0b8f68a94ff31113d176df596df1b6809bd7219b75d51faee1
Stable URL of this page
https://metraipolis.com/documento/dc_e12675f5507f

How to cite

Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A… — Europe PMC PMID:38976754 — Europe PMC (en), https://europepmc.org/article/MED/38976754 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e12675f5507f (Metraipolis archive dc_e12675f5507f, sha256 9aa362a6f33aab0b8f68a94ff31113d176df596df1b6809bd7219b75d51faee1)
BibTeX
@misc{dce12675f5507f,
  title = {Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A… — Europe PMC PMID:38976754},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38976754},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e12675f5507f; sha256 9aa362a6f33aab0b8f68a94ff31113d176df596df1b6809bd7219b75d51faee1},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38976754. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Since common diagnostic tests for gonorrhea do not provide information about susceptibility to antibiotics, treatment of gonorrhea remains empiric. Antibiotics used for empiric therapy are usually changed once resistance prevalence exceeds a certain threshold (e.g., 5%). A low switch threshold is intended to increase the probability that an infection is successfully treated with the first-line antibiotic, but it could also increase the pace at which recommendations are switched to newer antibiotics. Little is known about the impact of changing the switch threshold on the incidence of gonorrhea, the rate of treatment failure, and the overall cost and quality-adjusted life-years (QALYs) associated with gonorrhea. Methods and findings: We developed a transmission model of gonococcal infection with multiple resistant strains to project gonorrhea-associated costs and loss in QALYs under different switch thresholds among men who have sex with men (MSM) in the United States. We accounted for the costs and disutilities associated with symptoms, diagnosis, treatment, and sequelae, and combined costs and QALYs in a measure of net health benefit (NHB). Our results suggest that under a scenario where 3 antibiotics are available over the next 50 years (2 suitable for the first-line therapy of gonorrhea and 1 suitable only for the retreatment of resistant infections), changing the switch threshold between 1% and 10% does not meaningfully impact the annual number of gonorrhea cases, total costs, or total QALY losses associated with gonorrhea. However, if a new antibiotic is to become available in the future, choosing a lower switch threshold could improve the population NHB. If in addition, drug-susceptibility testing (DST) is available to inform retreatment regimens after unsuccessful first-line therapy, setting the switch threshold at 1% to 2% is expected to maximize the population NHB. A limitation of our study is that our analysis only focuses on the MSM population and does not consider the influence of interventions such as vaccine and common use of rapid drugs susceptibility tests to inform first-line therapy. Conclusions: Changing the switch threshold for first-line antibiotics may not substantially change the health and financial outcomes associated with gonorrhea. However, the switch threshold could be reduced when newer antibiotics are expected to become available soon or when in addition to future novel antibiotics, DST is also available to inform retreatment regimens.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS medicine, 2024 (prima pubblicazione 2024-07-08).
Identificativi: PMID 38976754 · PMCID PMC11262662 · DOI 10.1371/journal.pmed.1004424.
Descrittori MeSH principali: Gonorrhea; Anti-Bacterial Agents; Homosexuality, Male; Quality-Adjusted Life Years; Cost-Benefit Analysis.
Pagina: https://europepmc.org/article/MED/38976754 — https://doi.org/10.1371/journal.pmed.1004424. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T15:36:02.969Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.